Nov 7 2008, 05:27 AM
Gardasil, the vaccine against the very common sexually transmitted disease HPV (human papilloma virus) is now being tested in adult women, including a study in HIV-positive women. The vaccine is currently FDA-approved for girls and young women ages 13 to 24, but it has shown to be effective in women up to age 45. That research, however, did not include HIV-positive women, a group at great risk of HPV complications, including cervical cancer (cancer of the lower end of the uterus or womb). The study with positive women is from the AIDS Clinical Trials Group, and is study A5240. In Chicago, it is being conducted at Rush University Medical Center. Please e-mail Joan_A_Swiatek@Rush.edu for eligibility and enrollment information.